Allogene Therapeutics Inc
ALLO
Get informed when a big investor buys or sells
+ FollowMarket Cap$431.86M
Close$
$-0.14
111.4% downside
Current Fair Value
111.4% downsideOvervalued by 111.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $431.86 Million |
|---|---|
| Enterprise Value | $463.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.87 |
| Beta | 0.48 |
| Outstanding Shares | 328,930,269 |
Return
| Return on Equity | -37.94% |
|---|---|
| Return on Assets | -30.08% |
| Return on Invested Capital | -36.91% |
Valuation & Multiples
| P/E Ratio | -1.87 |
|---|---|
| PEG | 11.5 |
| Price to Sales | - |
| Price to Book Ratio | 1.25 |
| Enterprise Value to Revenue | 99.91 |
| Enterprise Value to EBIT | -2.42 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$2,500
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$2,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 56.08% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 95.74% |
|---|---|
| Total Invested | $11,928▼ 100.00% |
| Investors Holding | 2▼ 214.00% |
ESG Score
No data